Trade Report: Today, Pacira Pharmaceuticals’ (PCRX) “Buy” Rating Reiterate at Mizuho

Today, Pacira Pharmaceuticals’ (PCRX) “Buy” Rating Reiterate at Mizuho

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “buy” rating reiterated by equities research analysts at Mizuho in a report issued on Saturday. They presently have a $46.00 price target on the stock. Mizuho’s target price indicates a potential upside of 40.03% from the company’s current price.

A number of other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, November 21st. Wedbush reiterated an “outperform” rating and issued a $89.00 target price (down from $93.00) on shares of Pacira Pharmaceuticals in a research note on Sunday, November 6th. BMO Capital Markets reiterated a “hold” rating and issued a $35.00 target price on shares of Pacira Pharmaceuticals in a research note on Thursday, November 3rd. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, October 14th. Finally, Brean Capital began coverage on shares of Pacira Pharmaceuticals in a research note on Friday, October 7th. They issued a “hold” rating for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $71.18.

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 32.85 on Friday. Pacira Pharmaceuticals has a one year low of $30.25 and a one year high of $80.25. The firm’s market capitalization is $1.23 billion. The firm’s 50-day moving average is $34.21 and its 200 day moving average is $38.86.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 2nd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.22. The firm earned $68.40 million during the quarter, compared to analysts’ expectations of $67.16 million. Pacira Pharmaceuticals had a negative net margin of 13.37% and a negative return on equity of 1.52%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. Analysts forecast that Pacira Pharmaceuticals will post $0.55 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of Pacira Pharmaceuticals by 19.1% in the second quarter. FMR LLC now owns 5,567,088 shares of the company’s stock worth $187,778,000 after buying an additional 892,511 shares during the period. Vanguard Group Inc. raised its position in shares of Pacira Pharmaceuticals by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,587,221 shares of the company’s stock worth $87,268,000 after buying an additional 64,898 shares during the period. BlackRock Fund Advisors raised its position in shares of Pacira Pharmaceuticals by 5.7% in the third quarter. BlackRock Fund Advisors now owns 1,682,381 shares of the company’s stock worth $57,571,000 after buying an additional 90,693 shares during the period. Westfield Capital Management Co. LP raised its position in shares of Pacira Pharmaceuticals by 92.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,333,868 shares of the company’s stock worth $44,991,000 after buying an additional 640,814 shares during the period. Finally, State Street Corp raised its position in shares of Pacira Pharmaceuticals by 8.0% in the second quarter. State Street Corp now owns 1,197,912 shares of the company’s stock worth $40,406,000 after buying an additional 88,301 shares during the period.

About Pacira Pharmaceuticals

Related posts

Leave a Comment